Publications
714 results found
Hatzakis A, Wait S, Bruix J, et al., 2011, The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference, JOURNAL OF VIRAL HEPATITIS, Vol: 18, Pages: 1-16, ISSN: 1352-0504
- Author Web Link
- Cite
- Citations: 175
Anstee QM, Dhar A, Thursz MR, 2011, The role of hypercoagulability in liver fibrogenesis, CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, Vol: 35, Pages: 526-533, ISSN: 2210-7401
- Author Web Link
- Cite
- Citations: 71
Thursz M, Brown A, 2011, Can antiviral therapy of chronic hepatitis B prevent the development of hepatocellular carcinoma?, GUT, Vol: 60, Pages: 1025-1026, ISSN: 0017-5749
- Author Web Link
- Cite
- Citations: 7
Sangwaiya A, Manglam V, Busbridge M, et al., 2011, Blunted increase in serum hepcidin as response to oral iron in <i>HFE</i>-hemochromatosis, EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, Vol: 23, Pages: 721-724, ISSN: 0954-691X
- Author Web Link
- Cite
- Citations: 4
Wiersma ST, McMahon B, Pawlotsky J-M, et al., 2011, Treatment of chronic hepatitis B virus infection in resource-constrained settings: expert panel consensus., Liver Int, Vol: 31, Pages: 755-761
Most of the estimated 350 million people with chronic hepatitis B virus (HBV) infection live in resource-constrained settings. Up to 25% of those persons will die prematurely of hepatocellular carcinoma (HCC) or cirrhosis. Universal hepatitis B immunization programmes that target infants will have an impact on HBV-related deaths several decades after their introduction. Antiviral agents active against HBV are available; treatment of HBV infection in those who need it has been shown to reduce the risk of HCC and death. It is estimated that 20-30% of persons with HBV infection could benefit from treatment. However, drugs active against HBV are not widely available or utilized in persons infected with HBV. Currently recommended antiviral agents used for treatment of human immunodeficiency virus (HIV) infection do not adequately suppress HBV, which is of great concern for the estimated 10% of the HIV-infected persons in Africa who are co-infected with HBV. Progressive liver disease has been shown to occur in co-infected persons whose HBV infection is not suppressed. In view of these concerns, an informal World Health Organization consultation of experts concluded that: chronic HBV is a major public health problem in emerging nations; all HIV-infected persons should be screened for HBV infection; HIV/HBV co-infected persons should be treated with therapies active against both viruses and that reduce the risk of resistance; standards for the management of chronic HBV infection should be adapted to resource-constrained settings. In addition, a research agendum was developed focusing on issues related to prevention and treatment of chronic HBV in resource-constrained settings.
Knapp S, Warshow U, Ho KMA, et al., 2011, A Polymorphism in <i>IL28B</i> Distinguishes Exposed, Uninfected Individuals From Spontaneous Resolvers of HCV Infection, GASTROENTEROLOGY, Vol: 141, Pages: 320-U419, ISSN: 0016-5085
- Author Web Link
- Cite
- Citations: 68
Sauvage VR, Levene AP, Nguyen HT, et al., 2011, Multi-Excitation Fluorescence Spectroscopy for Analysis of Non-Alcoholic Fatty Liver Disease, LASERS IN SURGERY AND MEDICINE, Vol: 43, Pages: 392-400, ISSN: 0196-8092
- Author Web Link
- Open Access Link
- Cite
- Citations: 11
Pratsides LAE, Nehme J, Thursz MR, et al., 2011, CASE REPORT Jaundiced after a party, BRITISH MEDICAL JOURNAL, Vol: 342, ISSN: 0959-535X
- Author Web Link
- Cite
- Citations: 1
Thursz M, Yee L, Khakoo S, 2011, Understanding the Host Genetics of Chronic Hepatitis B and C, SEMINARS IN LIVER DISEASE, Vol: 31, Pages: 115-127, ISSN: 0272-8087
- Author Web Link
- Cite
- Citations: 75
Sangwaiya A, Dhar A, Siddiqui F, et al., 2011, TO STAIN HUH7 CELLS WITH HEPCIDIN USING IMMUNOHISTOCHEMISTRY, Annual Meeting on British-Society-of-Gasenterology, Publisher: B M J PUBLISHING GROUP, Pages: A184-A184, ISSN: 0017-5749
Sangwaiya A, Manglam V, Busbridge M, et al., 2011, BLUNTED INCREASE IN SERUM HEPCIDIN AS RESPONSE TO ORAL IRON IN HFE - HEMOCHROMATOSIS, Annual Meeting on British-Society-of-Gasenterology, Publisher: B M J PUBLISHING GROUP, Pages: A57-A57, ISSN: 0017-5749
Levene A, Kudo H, Thursz M, et al., 2011, Activating Autophagocytosis Decreases Fat Within the Liver, 199th Scientific Meeting of the Pathological-Society-of-Great-Britain-and-Ireland, Publisher: WILEY-BLACKWELL, Pages: S4-S4, ISSN: 0022-3417
Antoniades C, Taams L, Paris M, et al., 2011, CIRCULATING MONOCYTE ENDOTOXIN TOLERANCE IN ACUTE LIVER FAILURE: ROLE OF HEPATICALLY DERIVED IL-10, 46th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Publisher: ELSEVIER, Pages: S15-S15, ISSN: 0168-8278
Knapp S, Ho KM, Warshow U, et al., 2011, ABSENCE OF <i>IL</i>-<i>28</i>B PROTECTION IN INDIVIDUALS EXPOSED TO HEPATITIS C VIRUS DEMONSTRATES DISCRETE GENETIC PATHWAYS FOR PROTECTION AGAINST CHRONIC HCV INFECTION, 46th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Publisher: ELSEVIER, Pages: S38-S39, ISSN: 0168-8278
Thursz M, Corradini SG, Toniutto P, et al., 2011, PNPLA3 SEQUENCE VARIANT (RS738409) CONFERS SUSCEPTIBILITY TO LIVER DAMAGE AND CIRRHOSIS IN HCV RELATED LIVER DISEASE, 46th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Publisher: ELSEVIER, Pages: S469-S469, ISSN: 0168-8278
Concas D, Wu B, Kudo H, et al., 2011, VANIN-1 ACTIVITY MODULATES THE STEATOSIS-STEATOHEPATITIS TRANSITION IN PROGRESSIVE NON-ALCOHOLIC STEATOHEPATITIS, 46th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Publisher: ELSEVIER, Pages: S42-S43, ISSN: 0168-8278
Anstee QM, Concas D, Wu B, et al., 2011, A NOVEL MOUSE MODEL OF HEPATIC GLYCOGEN STORAGE DISEASE TYPE 3 IDENTIFIED USING A PHENOTYPE-DRIVEN ETHYL-NITROSOUREA (ENU) MUTAGENESIS SCREEN, 46th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Publisher: ELSEVIER, Pages: S353-S353, ISSN: 0168-8278
Antoniades CG, Quaglia A, Mitry R, et al., 2011, EXPANSION OF HEPATIC MACROPHAGES IN ACETAMINOPHEN-INDUCED ACUTE LIVER FAILURE: WHERE DO THEY COME FROM AND WHAT IS THEIR ROLE?, 46th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Publisher: ELSEVIER, Pages: S362-S362, ISSN: 0168-8278
Corradini SG, Burza MA, Thursz MR, et al., 2011, PNPLA3 sequence variant (RS738409) confers susceptibility to HCV related cirrhosis in Europeans, DIGESTIVE AND LIVER DISEASE, Vol: 43, Pages: S72-S72, ISSN: 1590-8658
Wadsworth CA, Ziprin P, Pelling MX, et al., 2011, A case of HGV-related epigastric pain, GUT, Vol: 60, Pages: 197-284, ISSN: 0017-5749
Malik R, Kennedy P, Suri D, et al., 2011, The role of liver fibrosis assessment in the management of patients with chronic hepatitis B infection: lessons learned from a single centre experience., Hepat Res Treat, Vol: 2011
Background & Aims. Assess the clinical utility of the Prati criteria and normal ALT (<40 IU/L) in a cohort of patients with chronic hepatitis B infection (CHB). Methods. Serology, radiology, and histology were obtained in 140 patients with CHB. Results. HBeAg(+) group: 7 patients (7/56-12% HBeAg(+) group) misclassified as "immunotolerant", with HBV DNA > 6 log copies/ml and normal ALT, who in fact had moderate/severe fibrosis on liver biopsy. HBeAg(-) group: 10 patients with normal ALT and moderate/severe fibrosis on liver biopsy; 4 of these patients had >3 log copies/ml HBV DNA levels and 6 patients misclassified as "inactive carriers" with negative HBV DNA levels normal ALT and moderate/severe fibrosis (6/84-7% HBeAg(-) group). Two male HBeAg(+) and three male HBeAg(-) patients with ALT between 20 and 30 IU/L and moderate/severe fibrosis on liver biopsy would have been further mischaracterised using the Prati criteria for normal ALT. Age and ethnic group were more important predictors of moderate/severe fibrosis in multivariate analysis. Conclusion. HBeAg status, age, ethnic origin with longitudinal assessment of LFTs and viral load should be studied in patients with "normal ALT" at the upper end of normal range (ALT 20-40 IU/L) to appropriately classify patients and identify patients for liver fibrosis assessment to inform treatment decisions.
Wiersma ST, McMahon B, Pawlotsky JM, et al., 2010, Treatment of chronic hepatitis B virus infection in resource-constrained settings: expert panel consensus., Liver Int
Most of the estimated 350 million people with chronic hepatitis B virus (HBV) infection live in resource-constrained settings. Up to 25% of those persons will die prematurely of hepatocellular carcinoma (HCC) or cirrhosis. Universal hepatitis B immunization programmes that target infants will have an impact on HBV-related deaths several decades after their introduction. Antiviral agents active against HBV are available; treatment of HBV infection in those who need it has been shown to reduce the risk of HCC and death. It is estimated that 20-30% of persons with HBV infection could benefit from treatment. However, drugs active against HBV are not widely available or utilized in persons infected with HBV. Currently recommended antiviral agents used for treatment of human immunodeficiency virus (HIV) infection do not adequately suppress HBV, which is of great concern for the estimated 10% of the HIV-infected persons in Africa who are co-infected with HBV. Progressive liver disease has been shown to occur in co-infected persons whose HBV infection is not suppressed. In view of these concerns, an informal World Health Organization consultation of experts concluded that: chronic HBV is a major public health problem in emerging nations; all HIV-infected persons should be screened for HBV infection; HIV/HBV co-infected persons should be treated with therapies active against both viruses and that reduce the risk of resistance; standards for the management of chronic HBV infection should be adapted to resource-constrained settings. In addition, a research agendum was developed focusing on issues related to prevention and treatment of chronic HBV in resource-constrained settings.
Sri-Ganeshan M, Sadiq F, Thursz M, 2010, Analysis of phosphodiesterase-12-A potential new target for therapeutic inhibtion of hepatiti s C virus replication, EUROPEAN JOURNAL OF MEDICAL RESEARCH, Vol: 15, Pages: 121-121, ISSN: 0949-2321
Fries L, Rodger A, Ijaz S, et al., 2010, CHRONIC HEPATITIS B VIRUS INFECTION IN THE UK: A MULTICENTRE STUDY OF CLINICAL AND VIROLOGICAL CHARACTERISTICS, 61st Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Publisher: WILEY-BLACKWELL, Pages: 675A-675A, ISSN: 0270-9139
Dhar A, Anstee QM, Cobbold JF, et al., 2010, ANTICOAGULATION FOR LIVER FIBROSIS: A PILOT STUDY IN HEPATITIS C INFECTED PATIENTS, 61st Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Publisher: WILEY-BLACKWELL, Pages: 1133A-1133A, ISSN: 0270-9139
- Author Web Link
- Cite
- Citations: 4
Dhar A, Anstee QM, Sadiq F, et al., 2010, FACTOR XA INHIBITION SUPPRESSES THIOACETAMIDE INDUCED LIVER FIBROSIS, 61st Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Publisher: WILEY-BLACKWELL, Pages: 1125A-1125A, ISSN: 0270-9139
- Author Web Link
- Cite
- Citations: 4
Antoniades CG, Mitry RR, Quaglia A, et al., 2010, HEPATIC MACROPHAGE POPULATION IN ACETAMINOPHEN-INDUCED LIVER FAILURE: WHERE DO THEY COME FROM AND WHAT IS THEIR ROLE?, 61st Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Publisher: WILEY-BLACKWELL, Pages: 612A-612A, ISSN: 0270-9139
Anstee QM, Concas D, Kudo H, et al., 2010, Impact of pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis, JOURNAL OF HEPATOLOGY, Vol: 53, Pages: 542-550, ISSN: 0168-8278
- Author Web Link
- Cite
- Citations: 121
Levene A, Kudo H, Thursz M, et al., 2010, Is Oil Red-O and Digital Image Analysis the Gold Standard for Quantifying Steatosis in the Liver?, 198th Scientific Meeting of the Pathological-Society-of-Great Britain-and-Ireland, Publisher: JOHN WILEY & SONS LTD, Pages: S50-S50, ISSN: 0022-3417
Ratziu V, Bellentani S, Cortez-Pinto H, et al., 2010, A position statement on NAFLD/NASH based on the EASL 2009 special conference, JOURNAL OF HEPATOLOGY, Vol: 53, Pages: 372-384, ISSN: 0168-8278
- Author Web Link
- Cite
- Citations: 755
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.